LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Bridget A. Ross Sells 2,500 Shares

Key Points

• Bridget A. Ross, Director of LeMaitre Vascular, sold 2,500 shares at an average price of $94.00, totalizing $235,000, representing a 46.16% decrease in her ownership.
• The company reported $0.60 earnings per share for the last quarter, exceeding estimates of $0.57, with a revenue of $63.15 million, a 15.0% increase year-over-year.
• LeMaitre Vascular declared a quarterly dividend of $0.20 per share, with an annualized yield of 0.8% for shareholders of record by August 21st.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) Director Bridget A. Ross sold 2,500 shares of the company's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $94.00, for a total transaction of $235,000.00. Following the completion of the sale, the director directly owned 2,916 shares in the company, valued at $274,104. This trade represents a 46.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

LeMaitre Vascular Stock Performance

NASDAQ LMAT traded up $0.78 during mid-day trading on Wednesday, reaching $95.16. 21,578 shares of the stock were exchanged, compared to its average volume of 188,963. The business's 50 day moving average is $83.82 and its 200-day moving average is $86.52. LeMaitre Vascular, Inc. has a 1 year low of $71.42 and a 1 year high of $109.58. The company has a market capitalization of $2.15 billion, a P/E ratio of 46.24, a P/E/G ratio of 2.38 and a beta of 0.79. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The firm had revenue of $63.15 million for the quarter, compared to the consensus estimate of $62.48 million. During the same period in the prior year, the firm posted $0.52 earnings per share. The firm's quarterly revenue was up 15.0% compared to the same quarter last year. On average, equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. LeMaitre Vascular's dividend payout ratio is 38.83%.

Analyst Upgrades and Downgrades

LMAT has been the topic of several recent research reports. Barrington Research raised shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective on the stock in a report on Wednesday, August 6th. Cantor Fitzgerald upped their price objective on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $98.00.

Institutional Trading of LeMaitre Vascular

A number of hedge funds have recently added to or reduced their stakes in LMAT. Geneva Capital Management LLC raised its position in LeMaitre Vascular by 6.0% during the second quarter. Geneva Capital Management LLC now owns 915,238 shares of the medical instruments supplier's stock worth $76,010,000 after acquiring an additional 51,489 shares during the period. Congress Asset Management Co. raised its position in LeMaitre Vascular by 4.6% during the second quarter. Congress Asset Management Co. now owns 673,968 shares of the medical instruments supplier's stock worth $55,973,000 after acquiring an additional 29,553 shares during the period. Geode Capital Management LLC raised its position in LeMaitre Vascular by 3.0% during the second quarter. Geode Capital Management LLC now owns 519,792 shares of the medical instruments supplier's stock worth $43,174,000 after acquiring an additional 15,036 shares during the period. Northern Trust Corp raised its position in LeMaitre Vascular by 5.4% during the first quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier's stock worth $28,993,000 after acquiring an additional 17,748 shares during the period. Finally, Envestnet Asset Management Inc. raised its position in LeMaitre Vascular by 6.8% during the second quarter. Envestnet Asset Management Inc. now owns 304,556 shares of the medical instruments supplier's stock worth $25,293,000 after acquiring an additional 19,447 shares during the period. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.